AlloVir, Inc.

ALVRNASDAQHealthcare

$9.81

+$0.39(+4.14%)

Market Cap$49475362

P/E Ratio—

52W High$24.15

52W Low$7.96

Avg Volume23K

Open$9.55

Beta0.62

Free Cash Flow Financials Revenue

AlloVir, Inc. (ALVR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

ALVR · free cash flow · updated Jun 9, 2026

Core FCF metrics

ALVR · FCF · TTM · margin & CAGR

Free cash flow was −$38.6M for FY2025 (fiscal year ending 2025-12-31), up 43.0% year-over-year

FY2025 Free Cash Flow−$38.6M▲ +43.0% YoY

Trailing 12M (TTM)−$42.7Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

ALVR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$38.4M(0M)−$38.6M▲ +43.0%—

FY2024−$67.7M(0M)−$67.7M▲ +45.6%—

FY2023−$124.5M(0M)−$124.5M▲ +12.3%—

FY2022−$142.1M(0M)−$141.9M▼ 33.5%—

FY2021−$106.3M(0M)−$106.3M▼ 74.2%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

ALVR · P/FCF · FCF yield · FCF per share

AlloVir, Inc. (ALVR) reported negative free cash flow of −$0.04B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

ALVR · cash flow statement · operating / investing / financing

For FY2025, AlloVir, Inc. generated −$38.4M in operating cash flow and spent 0M in capital expenditures, yielding −$38.6M in free cash flow.

Operating Activities

−$38.4M

Cash from core business operations

2025-12-31

Investing Activities

−$19.7M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$155.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$38.4M) − |CapEx| (0M) = FCF (−$38.6M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

ALVR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

AlloVir, Inc.YOU

ALVR

−$38.6M+43.0%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

AlloVir, Inc. (ALVR) reported free cash flow of −$38.6M for FY2025 (fiscal year ending 2025-12-31), up 43.0% year-over-year.

Based on available data, AlloVir, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $1.9M in FY2018.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

ALVR free cash flow · 8 questions

AlloVir, Inc. free cash flow was −$38.6M for FY2025, up 43.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$42.7M.

ALVR free cash flowALVR FCFALVR FCF 2025ALVR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · AlloVir, Inc. · AlloVir, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026